植入式心脏装置患者的动静脉瘘与移植物构建:侧别是否有影响?
单中心回顾性分析2008至2016年44例终末期肾病合并心脏植入式电子装置(CIED)患者,其中28例有动静脉通路随访(13例同侧、15例对侧)。同侧与对侧通路一期通畅时间分别为20.2和22.2个月,二期干预后平均通畅时间分别为39和48.8个月;同侧通路6个月和1年一期通畅率分别为69.2%和53.8%。作者认为CIED可能导致通路狭窄或闭塞,但通畅率仍可接受,中心静脉通畅时不应放弃同侧通路。
要点
- 同侧与对侧动静脉通路一期通畅时间分别为20.2和22.2个月。
- 二期干预后同侧与对侧平均通畅时间分别为39和48.8个月。
- 同侧通路6个月和1年一期通畅率分别为69.2%和53.8%。
核心结论
- CIED可能导致动静脉通路狭窄或闭塞,但与肾脏病结局质量倡议指南相比,6个月和1年的一期辅助通畅率及二期通畅率仍可接受。
- 作者认为,尽管存在CIED,若中心静脉系统通畅,手术决策不应导致放弃同侧通路。
研究设计与样本
- 2008至2016年单中心回顾性 review,识别所有接受CIED且诊断为终末期肾病的患者。
- 查询病历确定每例患者的透析通路及通路位于CIED同侧或对侧。
- 主要结局为一期和二期通畅率。
主要发现
- 共识别44例终末期肾病合并CIED患者,其中28例有动静脉瘘或移植物(13例同侧、15例对侧)并接受通路随访。
- 两组各有3例一期失败。
- 对于已开始透析后才植入CIED的患者,通畅时间从心脏装置植入时计算。
- 同侧与对侧通路一期通畅时间分别为20.2和22.2个月。
- 二期干预后同侧与对侧平均通畅时间分别为39和48.8个月。
临床怎么用
- 当前建议提出将通路置于CIED对侧,因担心增加中心静脉狭窄和通路失败。
- 作者认为,尽管存在CIED,若中心静脉系统通畅,手术决策不应导致放弃同侧通路。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited reports have documented the effect cardiac implantable electronic devices (CIEDs) have on arteriovenous (AV) access patency. Current recommendations suggest placing the access on the contralateral side of the CIEDs, as there is concern for increased central venous stenosis and access failure. The goal of this study is to review our single-center AV access patency rates for dialysis patients with an ipsilateral or contralateral side CIED. METHODS: A retrospective review was performed from 2008 to 2016 at a single institution identifying all patients who have received a CIED and the diagnosis of end-stage renal disease (ESRD). Medical records were queried to identify each patient's dialysis access and whether it was ipsilateral or contralateral to the CIED. Primary outcomes of study were primary and secondary patency rates. RESULTS: A total of 44 patients were identified to have ESRD and CIED. Of these patients, 28 patients with fistulas or grafts (13 ipsilateral and 15 contralateral) had follow-up with regards to their AV access. There were 3 primary failures in both groups. For patients who had the CIED placed after already starting the dialysis, patency was based on when the cardiac device was implanted. Primary patency for ipsilateral and contralateral access was 20.2 and 22.2 months, respectively. With secondary interventions, ipsilateral and contralateral mean patency was 39 and 48.8 months, respectively. Six-month and 1-year primary patency for arteriovenous fistula or arteriovenous graft on patients with ipsilateral access was 69.2% and 53.8%, respectively. Ipsilateral 1-year cumulative patency was 39 months. CONCLUSIONS: CIED may lead to stenosis or occlusion to one's AV access; however, primary assisted and secondary patency rates are still acceptable at 6 months and 1 year compared to Kidney Disease Outcomes Quality Initiative guidelines. Despite a CIED, a surgeon's algorithm should not lead to the abandonment of an ipsilateral access if the central venous system is patent.
引用
- Sgroi MD, McFarland G, Itoga NK, et al. Arteriovenous Fistula and Graft Construction in Patients with Implantable Cardiac Devices: Does Side Matter? Ann Vasc Surg. 2018. PMID: 30339901. doi:10.1016/j.avsg.2018.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。